Gene therapy restores immune function in 95% of ADA-SCID children

An international trial using lentiviral gene therapy has produced successful results for children with ADA-SCID, a rare genetic disorder that leaves the immune system non-functional. Of the 50 children who participated in the study, the treatment restored immune function in 48, a success rate of 96%. These findings, published in the New England Journal of Medicine on 15 September 2026, illustrate how gene therapy can address severe genetic conditions.

The disorder is defined by a lack of the enzyme adenosine deaminase, which is vital for a working immune system. Without it, children are extremely vulnerable to infection and often live in isolation or require constant medical care. In this trial, researchers used a lentiviral vector to deliver a working copy of the ADA gene into the patients' own cells. This allowed their bodies to produce the missing enzyme and rebuild their immune defenses from within.

Research took place across several institutions, including UCLA, Great Ormond Street Hospital, and the National Institutes of Health (NIH). Each site provided the specialized resources and expertise needed for such a complex study. Beyond the clinical success, the project serves as an example of how multi-institutional collaboration can drive significant progress in modern medicine.

The benefits of this therapy reach further than the individual cases. By restoring natural immunity, the treatment improves the daily lives of these children and reduces the long-term demands on healthcare providers. It marks a move toward therapies that treat the underlying cause of a genetic disease rather than just its symptoms, potentially paving the way for similar research into other conditions.

These results suggest that gene therapy may eventually become a standard care option for ADA-SCID and other similar disorders. Long-term monitoring of the participants will continue to ensure the effects remain stable over time. As the field matures, these advancements point toward a new landscape for treating rare diseases, providing a practical path forward for families facing these conditions.